- Home
- GLMD vs SLXN Comparison
GLMD vs SLXN Comparison
Compare GLMD & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- SLXN
- Stock Information
- Founded
- GLMD 2000
- SLXN 2008
- Country
- GLMD Israel
- SLXN Israel
- Employees
- GLMD N/A
- SLXN N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- SLXN
- Sector
- GLMD Health Care
- SLXN
- Exchange
- GLMD Nasdaq
- SLXN NYSE
- Market Cap
- GLMD 4.5M
- SLXN 4.3M
- IPO Year
- GLMD 2014
- SLXN N/A
- Fundamental
- Price
- GLMD $1.46
- SLXN $0.94
- Analyst Decision
- GLMD
- SLXN Strong Buy
- Analyst Count
- GLMD 0
- SLXN 1
- Target Price
- GLMD N/A
- SLXN $5.00
- AVG Volume (30 Days)
- GLMD 2.6M
- SLXN 955.8K
- Earning Date
- GLMD 05-29-2025
- SLXN 05-21-2025
- Dividend Yield
- GLMD N/A
- SLXN N/A
- EPS Growth
- GLMD N/A
- SLXN N/A
- EPS
- GLMD N/A
- SLXN N/A
- Revenue
- GLMD N/A
- SLXN N/A
- Revenue This Year
- GLMD N/A
- SLXN N/A
- Revenue Next Year
- GLMD N/A
- SLXN N/A
- P/E Ratio
- GLMD N/A
- SLXN N/A
- Revenue Growth
- GLMD N/A
- SLXN N/A
- 52 Week Low
- GLMD $1.33
- SLXN $0.21
- 52 Week High
- GLMD $23.80
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- GLMD 33.38
- SLXN N/A
- Support Level
- GLMD $1.33
- SLXN N/A
- Resistance Level
- GLMD $1.55
- SLXN N/A
- Average True Range (ATR)
- GLMD 0.33
- SLXN 0.00
- MACD
- GLMD -0.04
- SLXN 0.00
- Stochastic Oscillator
- GLMD 5.90
- SLXN 0.00
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.